In a regulatory development that could affect near-term operations, Dr. Reddy’s Laboratories has received seven observations from the U.S. Food and Drug Administration (USFDA) following a routine inspection of its manufacturing facility located in Srikakulam, Andhra Pradesh. The inspection, which concluded recently, resulted in the issuance of a Form 483, a standard procedure wherein the USFDA notes areas of concern that require corrective action. While no critical findings were reported, the company is expected to respond promptly, addressing compliance gaps to avoid escalation.
